- Home
- CURV vs CHRS Comparison
CURV vs CHRS Comparison
Compare CURV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- CHRS
- Stock Information
- Founded
- CURV 2001
- CHRS 2010
- Country
- CURV United States
- CHRS United States
- Employees
- CURV N/A
- CHRS N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURV Consumer Discretionary
- CHRS Health Care
- Exchange
- CURV Nasdaq
- CHRS Nasdaq
- Market Cap
- CURV 185.4M
- CHRS 159.2M
- IPO Year
- CURV 2021
- CHRS 2014
- Fundamental
- Price
- CURV $1.64
- CHRS $1.71
- Analyst Decision
- CURV Hold
- CHRS Strong Buy
- Analyst Count
- CURV 5
- CHRS 4
- Target Price
- CURV $3.03
- CHRS $4.51
- AVG Volume (30 Days)
- CURV 648.2K
- CHRS 1.2M
- Earning Date
- CURV 09-04-2025
- CHRS 11-05-2025
- Dividend Yield
- CURV N/A
- CHRS N/A
- EPS Growth
- CURV N/A
- CHRS N/A
- EPS
- CURV 0.03
- CHRS 1.55
- Revenue
- CURV $1,068,099,000.00
- CHRS $272,209,000.00
- Revenue This Year
- CURV N/A
- CHRS N/A
- Revenue Next Year
- CURV N/A
- CHRS $109.48
- P/E Ratio
- CURV $56.06
- CHRS $1.10
- Revenue Growth
- CURV N/A
- CHRS 52.33
- 52 Week Low
- CURV $1.62
- CHRS $0.66
- 52 Week High
- CURV $7.19
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- CURV 33.71
- CHRS 69.28
- Support Level
- CURV $1.63
- CHRS $1.56
- Resistance Level
- CURV $1.80
- CHRS $1.78
- Average True Range (ATR)
- CURV 0.09
- CHRS 0.12
- MACD
- CURV 0.01
- CHRS 0.00
- Stochastic Oscillator
- CURV 3.03
- CHRS 81.71
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.